The impact of virulence factor expression in oral biofilms for the immune response

Not Applicable

• Conditions: Young healthy volunteers; K05.0; Acute gingivitis

• Registration Number: DRKS00003366
• Lead Sponsor: Medizinische Hochschule Hannover

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-11-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

No history of any systemic disease

Exclusion Criteria

Systemic diseases, periodontitis or caries, Medications that interfere with immune response 6 months before the start of the study, pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The systemic concentrations of hsCRP will be determined by immunnephelometrie at day 0, 21 and 42 in serum.

Secondary Outcome Measures

Name	Time	Method
The systemic concentration of IL-6, MCP-1 will be measured in vitro by ELISA, for monocyte activation established assays will be used and the microbial diversity as well as the expression of virulence factors will be determined by sequencing techniques. All measurements will be performed at day 0, 21 and 42.